Bioterrorism: A Billion-Plus for Countermeasures, But Also New Strings
This article was originally published in Start Up
Executive Summary
The new US bioterrorism bill will direct hundreds of millions of dollars toward bolstering the US pharmaceutical stockpile. At the same time, it imposes reporting and other obligations on companies. On the other hand, some regulatory burdens on companies will be eased. And because FDA may now find now in an unusual dual position with respect to risk taking--promoting industry while at the same time regulating--it could create a different dynamic with companies.